Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(TSX:BLCO)

15.72 +0.17 (+1.09%)
Streaming Delayed Price Updated: 10:21 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 350
Open 15.55
Bid (Size) 15.66 (1)
Ask (Size) 15.69 (4)
Prev. Close 15.55
Today's Range 15.55 - 15.72
52wk Range 14.56 - 29.37
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
-39.4%
-39.4%
1 Month
-16.9%
-16.9%
3 Month
-30.7%
-30.7%
6 Month
-42.5%
-42.5%
1 Year
-22.2%
-22.2%

More News

Read More
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces First-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Responds to Rumors of a Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Third-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Second-Quarter 2024 Results
From Bausch + Lomb Corporation
Via Business Wire

Frequently Asked Questions

Is BLCO publicly traded?
Yes, BLCO is publicly traded.
What exchange does BLCO trade on?
BLCO trades on the Toronto Stock Exchange
What is the ticker symbol for BLCO?
The ticker symbol for BLCO is BLCO on the Toronto Stock Exchange
What is the current price of BLCO?
The current price of BLCO is 15.72
When was BLCO last traded?
The last trade of BLCO was at 06/02/25 10:21 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.